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DISCLOSURES
Drs. Click and Hagemeier DO NOT have a 
financial interest/arrangement or affiliation with 
one or more organizations that could be perceived 
as a real or apparent conflict of interest in the 
context of the subject of this presentation.
OBJECTIVES
 Describe Neonatal Abstinence Syndrome (NAS) trends in Tennessee
 Explain the applicability of the Theory of Planned Behavior to prescriber 
and dispenser substance use prevention behaviors
 Describe preliminary study outcomes 
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NEONATAL ABSTINENCE SYNDROME
Neonatal Abstinence Syndrome (NAS) is a 
withdrawal syndrome that occurs when a 
baby is born dependent upon substances 
taken by the mother during pregnancy. 
NAS can be associated with:
 Prescription drugs obtained with prescription
 Includes women on pain therapy or replacement therapy
 Prescription drugs obtained without prescription
 Illicit drugs
NAS SYMPTOMS
Opioid withdrawal symptoms primarily related to:
 Central Nervous System:
 Seizures 
 Tremors
 Hyperactivity
 Gastrointestinal System:
 Poor feeding
 Vomiting
 Poor weight gain 
 Diarrhea
 Uncoordinated sucking
NAS SYMPTOMS
Opioid withdrawal symptoms:
May appear as early as within the first 24 hours
May take as many as 4-5 days to appear
Occur in 55-94% of exposed infants
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NAS IN TENNESSEE
 The incidence of NAS has increased by more than 10-fold during the 
last decade in Tennessee
 NAS incidence highest in East TN
 The substance of exposure is typically an opioid, which may or may not 
have been prescribed to the mother.
 Babies with NAS have significantly longer hospital stays than otherwise 
healthy infants and may be at risk for developmental delays or other 
health concerns as they grow.
 The average cost to Medicaid (TennCare) for caring for an affected infant is over 
$66,000.
 Infants with NAS are more likely to enter state custody, placing an 
additional toll on the state’s child welfare system.
NAS AND TN
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INSERT 2014 WEEKLY GRAPH
INSERT 2015 WEEKLY GRAPH
PREVENTION VS. TREATMENT
 Maternal substance use prevention
 Appropriate use
 Risk awareness
 Contraception
 Maternal substance use treatment
 4.4% of pregnant women report past month illicit drug use (NSDUH, 2011)
 Withdrawal during pregnancy is not recommended (ACOG, 2012)
 Methadone had been gold standard, but recent evidence supports use of  
buprenorphine (Jones et al, NEJM 2010)
 ~55% of NAS cases in TN report supervised replacement therapy as source of 
medication  
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PREVENTION BEHAVIORS ARE 
ESSENTIALLY UNEXPLORED
STUDY RESEARCH QUESTIONS
What are the attitudes, beliefs, and behaviors of Tennessee 
prescribers and dispensers specific to substance use in 
pregnancy and NAS primary prevention?
 How do prescriber/dispenser perceptions of and behaviors 
regarding substance use in pregnancy and NAS prevention differ 
across prescriber/dispenser characteristics?
What is the impact of a pilot NAS primary prevention 
academic detailing intervention with AppNET prescribers 
and buprenorphine prescribers on NAS primary prevention 
attitudes, beliefs, and behaviors? 
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METHODS
TPB instruments constructed 
 Stratified random samples selected (N=100 each)
 Buprenorphine “in-office” treatment authorized
 Pain management clinic directors
 Community pharmacists
 Primary care physicians
 Primary care NPs/PAs
 Pre-notification  Mailing #1 Reminder  Mailing #2 Telephone 
follow-up
SMALL GROUP ACTIVITY
PRELIMINARY RESULTS
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PRESCRIBERS
Prescriber Category
PCPs Bup. Prescripbers Pain Clinic 
Directors
Total
Mean N Std. 
Dev
Mean N Std. 
Dev
Mean N Std. 
Dev
Mean N Std. 
Dev
Discuss the risks of opioid use during pregnancy? 5.80 10 4.315 8.50 12 3.529 9.06 18 2.754 8.08 40 3.598
Discuss the patient's risk of physical dependence and 
addiction to opioids?
8.90 10 2.514 9.58 12 1.443 9.71 17 .686 9.46 39 1.553
Discuss the potential of physical dependence to and 
withdrawal from opioids in a newborn
5.80 10 4.315 6.75 12 4.808 8.67 18 3.144 7.38 40 4.081
Discuss the results of a controlled substance monitoring 
database query with the patient? 5.50 10 3.536 6.82 11 2.994 9.38 16 1.628 7.57 37 3.087
Discuss a birth control plan when opioids are initiated? 5.70 10 4.498 8.08 12 3.630 7.61 18 4.075 7.28 40 4.064
Recommend long-acting, reversible contraception (LARC) 
to patients on opioids? 3.70 10 4.244 5.50 12 4.079 6.59 16 4.022 5.49 38 4.157
Direct patients to community resources through which 
long-acting, reversible contraception (LARC) can be 
accessed?
3.50 10 4.601 4.33 12 3.725 6.00 17 4.637 4.85 39 4.386
Document the type of contraception used by the patient? 6.73 11 4.563 8.36 11 3.107 8.33 15 3.619 7.86 37 3.758
Discuss the patient's pregnancy status at each visit if on 
long-term opioids?
5.27 11 4.519 7.92 12 3.343 8.33 18 3.361 7.39 41 3.833
Discuss the expectation that hte patient inform you if she 
becomes, or plans to become, pregnant? 6.80 10 4.104 9.83 12 .577 9.33 18 1.782 8.85 40 2.617
Administer a pregnancy test prior to the initiation of opioid 
therapy?
4.60 10 4.402 7.33 12 3.750 7.35 17 4.372 6.64 39 4.264
Obtain a patient's personal history of drug abuse prior to 
initiating therapy? 8.91 11 2.212 10.00 12 .000 9.83 18 .707 9.63 41 1.280
Conduct a drug abuse risk assessment prior to prescribing 
an opioid medication?
8.20 10 2.741 8.33 12 2.462 9.94 18 .236 9.03 40 2.044
Discuss your concern with a patient regarding her drug-
taking behaviors warranted?
8.91 11 1.973 10.00 12 .000 9.56 18 1.338 9.51 41 1.381
Verbally refer a patient for drug abuse treatment when 
warranted? 8.64 11 3.233 9.09 11 3.015 9.29 17 2.257 9.05 39 2.714
DISPENSERS
N Mean Std. Deviation
Counsel on the indication for the prescribed medication? 15 7.93 2.712
Ask about pregnancy status? 15 3.80 4.427
Document pregnancy status in the patient's medication profile? 15 2.80 4.127
Discuss the risks of prescription opioid use during pregnancy? 14 4.86 4.185
Discuss the risk of physical dependence and addiction to opioids? 15 6.27 3.882
Counsel on the importance of long-acting, reersible contraception 
(LARC)?
15 2.07 3.218
Ask if the patient has questions about the prescribed medication? 15 9.87 .516
Conduct a risk assessment or drug abuse screening prior to dispensing? 14 3.50 4.363
Conduct a controlled substance monitoring database (CSMD) query prior 
to dispensing?
15 8.27 2.815
Direct to community resources through which long-acting, reversible 
contraception (LARC) can be accessed?
15 1.60 3.066
Document the type of contraception to be used while taking the 
prescription opioid?
15 1.73 3.150
Communicate with the patient's prescriber's office to verify the 
prescription opioid is appropriate therapy?
15 3.27 4.284
Discuss the need to notify the prescriber if the patient becomes, or plans 
to become, pregnant?
15 4.13 4.274
Discuss your concern regarding the patient's drug taking behaviors when 
warranted?
15 4.73 4.399
Verbally refer for drug abuse treatment when warranted? 14 4.00 4.368
NEXT STEPS
 Pilot intervention: 
 Trained academic detailers will provide an educational outreach program to ~50% of 
survey respondents from PCP and buprenorphine prescriber cohorts. 
 Detailers will provide face-to-face presentations within participants’ clinic settings.
 Post-Intervention Survey Administration & Data Analysis
 Repeat survey with all respondents in PCP and buprenorphine prescriber cohorts. 
 Evaluate change in perceptions and behaviors between pre/post
 Differences in perceptions and behavior across cohorts.
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QUESTIONS?
